Initiate a Phase 2a combination clinical trial of AB-729 with vebicorvir and an NrtI
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Jan 2021
- Due
- 30 Jun 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate a Phase 2a combination clinical trial to evaluate AB-729 in combination with Assembly Biosciences’ lead core/capsid inhibitor candidate vebicorvir (VBR) and a nucleos(t)ide reverse transcriptase inhibitor (NrtI) for the treatment of subjects with chronic”
What we found
Evidence strength A What the grades mean
The company did not initiate the trial by the first half of 2021; filings indicate enrollment was ongoing as of August 2021, implying the trial started after the June 30, 2021 deadline.
-
A Arbutus Biopharma Corp 8-K filed 2021-07-14
“Initiate a Phase 2 combination clinical trial to evaluate AB - 729 in combination with Assembly Biosciences’ lead core/capsid inhibitor candidate vebicorvir (VBR) and an NrtI 1H” ✓ confirmed on the page
-
A Arbutus Biopharma Corp 10-Q filed 2021-08-05
“Through our collaboration with Assembly, we are enrolling subjects in a Phase 2a proof-of-concept clinical trial” ✓ confirmed on the page
Market reaction: the shares moved +11.2% against the S&P 500 over the three sessions around the disclosure (4 Aug 2021 to 9 Aug 2021). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2a combination clinical trial
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory, Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Arbutus Biopharma Corp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ABUS-022347 · Corrections policy